CLINDAMYCIN PALMITATE HYDROCHLORIDE
Clinical safety rating: safe
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
Clindamycin palmitate hydrochloride is a prodrug that is hydrolyzed in vivo to clindamycin. Clindamycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking peptide bond formation. It also inhibits the early stages of protein synthesis by interfering with the initiation complex.
| Metabolism | Clindamycin is metabolized primarily by the liver, undergoing N-demethylation and sulfoxidation, with involvement of CYP3A4. The prodrug clindamycin palmitate hydrochloride is hydrolyzed by esterases in plasma and tissues to active clindamycin. |
| Excretion | Approximately 10% of the dose is excreted unchanged in urine; the remainder is eliminated as inactive metabolites via bile (about 30–40%) and feces (about 50–60%). Renal clearance is minor and dosing adjustment is not typically required in renal impairment. |
| Half-life | Terminal elimination half-life is approximately 2.4–3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8–10 hours. |
| Protein binding | Clindamycin is approximately 60–94% bound to plasma proteins, primarily to albumin and α1-acid glycoprotein. Binding is concentration-dependent and decreases with higher drug concentrations. |
| Volume of Distribution | Volume of distribution is approximately 0.6–1.2 L/kg, indicating extensive distribution into body tissues. It penetrates well into bone, abscesses, and respiratory secretions but poorly into cerebrospinal fluid. |
| Bioavailability | Oral bioavailability of clindamycin palmitate hydrochloride is approximately 50–60% after conversion to active clindamycin. The palmitate ester is hydrolyzed in the gastrointestinal tract to release active clindamycin base. Food does not significantly affect absorption. |
| Onset of Action | For oral administration (as clindamycin palmitate hydrochloride), onset of action is approximately 1–2 hours after ingestion, corresponding to peak serum concentrations of active clindamycin. For intramuscular administration, onset is similar, with peak levels at 1–3 hours. |
| Duration of Action | Duration of action is approximately 6–8 hours for susceptible organisms, supporting a dosing interval of 6–8 hours. Clinical effect persists as long as serum concentrations exceed the MIC of the pathogen. |
150-300 mg orally every 6 hours. Maximum dose: 1.8 g/day.
| Dosage form | FOR SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <30 mL/min), consider extending interval to every 8-12 hours. |
| Liver impairment | No specific guidelines available. Use with caution in severe hepatic impairment. |
| Pediatric use | 8-16 mg/kg/day divided every 6-8 hours orally. Maximum dose: 450 mg/day for children <40 kg. |
| Geriatric use | No specific dose adjustment required, but monitor for gastrointestinal side effects and renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
| FDA category | Human |
| Breastfeeding | Clindamycin is excreted into human breast milk in low levels (M/P ratio approximately 0.5-1.0). Concentrations in milk are typically subtherapeutic for infants. However, there is a potential for gastrointestinal effects such as diarrhea or alteration of infant gut flora. Breastfeeding is generally considered acceptable if the benefit outweighs the risk; monitor infant for signs of gastrointestinal disturbance. |
| Teratogenic Risk |
■ FDA Black Box Warning
Clindamycin can cause severe and sometimes fatal colitis, including pseudomembranous colitis, due to Clostridium difficile overgrowth. This can occur during or after treatment and may range from mild diarrhea to fatal colitis. Clindamycin should be prescribed only for serious infections where less toxic agents are inappropriate.
| Common Effects | Diarrhea (including C. difficile) |
| Serious Effects |
["Hypersensitivity to clindamycin, lincomycin, or any component of the formulation","History of clindamycin-associated colitis or antibiotic-associated colitis","Concomitant administration with erythromycin (antagonism in vitro)","Use in patients with meningitis (inadequate CSF penetration)"]
| Precautions | ["Risk of Clostridium difficile-associated diarrhea (CDAD) and pseudomembranous colitis","May cause overgrowth of non-susceptible organisms, including fungi","Use with caution in patients with a history of gastrointestinal disease, particularly colitis","Use with caution in patients with hepatic impairment; monitor liver function","May cause neuromuscular blockade; use with caution in patients receiving neuromuscular blocking agents","Clindamycin palmitate hydrochloride contains sodium; consider in patients with sodium restriction"] |
Loading safety data…
| Clindamycin palmitate hydrochloride is a pregnancy category B drug. Animal reproduction studies have not shown fetal harm, but adequate human studies in pregnant women are lacking. No teratogenic effects have been consistently reported in first trimester exposures. Second and third trimester use is considered safe, although rare cases of pseudomembranous colitis have been reported in neonates after maternal use. Overall, fetal risk is low, but caution is advised. |
| Fetal Monitoring | No specific maternal-fetal monitoring is required. Standard obstetric monitoring is recommended. Mothers should be monitored for signs of Clostridioides difficile infection (diarrhea, colitis). Fetal monitoring is not necessary unless indicated by maternal condition. |
| Fertility Effects | Clindamycin has no known significant effects on human fertility. Animal studies have not demonstrated impaired fertility. No specific reproductive toxicity has been reported at therapeutic doses. |